About US
Contact us
-
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analystAbbVie has held high hopes for newcomers Skyrizi and Rinvoq as post-Allergan merger business drivers with the ongoing decline of Humira. But with prescription figures and market access tracking way a2019/11/20
-
Bankrupt Insys offers to turn out its almost empty pockets for plaintiffsAmidst a "fire sale" restructuring of bankrupt Insys, the former maker of notorious fentanyl spray Subsys, opioid plaintiffs are still hoping to pick some meat off the drugmaker's bones. And now, Ins2019/11/19
-
Amgen juices up sales outlook amid high hopes for Celgene castoff OtezlaWhen Amgen said it would hand over $13.4 billion forCelgene’s hit psoriasis drug Otezla in August,analysts agreed it had overpaid by $2 billion. But they also predicted Amgen’s experience turning imm2019/11/19
-
J&J now has to fight thousands more Risperdal claims, thanks to Pennsylvania's high courtJohnson & Johnson has been battlinglegal issues on several fronts—ranging from opioids to talc to medical devices—and Wednesday, its fight got a little tougher. Pennsylvania’s Supreme Courtruledt2019/11/18
-
Sanofi CEO's strategy blueprint may include consumer health spinoff or merger: BloombergSanofi CEO Paul Hudson has been on the job for just over two months, and he's prepping for a big strategy reveal next month. One thing that might be behind that curtain? A sale or spinoff of the comp2019/11/18
-
Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decadeNovo Nordisk, the world's biggest insulin producer,has set itself an unaccustomed task: Expand beyond diabetes. Wednesday, it outlined just how it plans to do that and how it plans to measure its pro2019/11/15
-
Alnylam wins FDA nod for $575,000 liver med Givlaari despite safety flagsAlnylam is facing a major challenger to its first approved drug, Onpattro, from Pfizer's Vyndaqel just over a year into its launch. But the company now has another drug approval to bolster its portfo2019/11/15
-
Bristol's Opdivo-Yervoy combo fails to top Opdivo in adjuvant melanomaBristol-Myers Squibb’s Opdivo-Yervoy combo has changed the game in late-stage melanoma, but it's hit a roadblock in expanding to post-surgery treatment. In patients withadvanced cancer but no evidenc2019/11/14
-
FDA Commissioner nominee Hahn promises to put science above politicsThe would-be replacement for departed FDA Commissioner Scott Gottlieb faced a Senate committee's grilling Wednesday, and he supported drug-pricing action—and science. During the hearing of the U.S. S2019/11/14
-
Teva forecasts 'tenfold' growth for new launch Austedo. Why don't analysts agree?Riding high on the launch of Huntingson's disease and tardive dyskinesia (TD) med Austedo, Teva is looking for "tenfold" patient growth in the drug's future, CEO Kare Schultz said. But analysts aren'2019/11/13